Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.
about
Carcinoid tumorsInherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversiesMedical treatment for gastro-entero-pancreatic neuroendocrine tumoursStreptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment StratificationBiological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategyChemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma).Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group.Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignanciesLarge cell neuroendocrine carcinoma of the rectum presenting with extensive metastatic disease.Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors.A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesisA multimodal approach to the management of neuroendocrine tumour liver metastasesBehavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs).Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms.Large cell neuroendocrine carcinoma of the colon: A rare and aggressive tumorLymph nodes and survival in pancreatic neuroendocrine tumors.Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experienceTat-induced FOXO3a is a key mediator of apoptosis in HIV-1-infected human CD4+ T lymphocytes.The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure.Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers.Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.Translation of molecular pathways into clinical trials of neuroendocrine tumors.Treatment options for unresectable neuroendocrine liver metastases.Streptozocin-based chemotherapy is not history in neuroendocrine tumours.Non-functional pancreatic neuroendocrine tumor as an incidentaloma--a case report and review of literature.Ki-67 is a reliable pathological grading marker for neuroendocrine tumors.The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation.Genetics and epigenetics in small intestinal neuroendocrine tumours.In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines.
P2860
Q24614827-7926B6D7-DA8B-4D93-87A7-A864327C7E28Q24647838-916A1854-628E-44C6-81B2-0A77821A87AAQ26751659-BFA78BDC-AD28-4191-82E9-52E6ACC21B8BQ28551275-2F0027F1-602B-4BCD-A0BD-E2BA229E5715Q33669457-9522F20E-1342-4BA7-8C2B-C4B64D082B52Q33783119-656A316D-7731-4F10-8972-8D33C75D912AQ33801620-6CF16CC7-B2C7-4897-9826-2632EC703D3FQ33894587-BE81C04C-67CD-4DF2-A561-580EACDAFF1DQ33901099-B83CAEA7-D6EE-4454-9C9B-90045860D7BDQ34003699-73A74C27-D3F1-498E-A2A2-F26279054824Q34013901-1D8F8550-556B-4936-A38B-7F2B345AD135Q34256413-692C1043-1DAA-4770-A101-F99606CD3142Q34414279-A91FC7CD-2FD2-4334-BB47-BCF032ABAEF1Q35661980-922D9010-28F1-4789-8935-797414F3DF0AQ35683181-AE90AAA6-7977-4A03-9982-6B38B26DFA05Q35810562-BAFBDCFD-7AA6-470A-AD83-D661E5D12875Q35857794-A8385F21-DE12-4DE6-A8A1-3E764104BFB5Q35934322-9030F617-E08A-4846-A75C-E7E289458198Q36041024-3F926C78-1AE1-4D1A-A45F-2EDCAAA588E3Q36097210-EAE47246-2865-4A75-A777-1F82AB8AE6B8Q36250472-CB009DD3-5849-4604-A076-E5F212848716Q36288817-585A429E-363A-4135-A4E1-1714F469B3B2Q36936986-E02A1404-B20C-4A66-AE6D-877A54F680B0Q37150920-1C10FB1C-B472-442D-8782-353C325A7DADQ37372483-08E3B293-CB0D-4FC9-B58C-9971380D0F4CQ37400665-D602A678-92CF-4F67-BE67-8B705F25BDDAQ37688704-7A8CFF58-1B34-4BDD-9D47-70A521EB7632Q37765569-9A1C1D16-080A-40CC-9ED2-4EF81C99FAE1Q37846130-C5300233-E054-4634-BC86-62D89D31AED8Q37962416-BF4F8ED5-5859-4E31-8F6E-50141ECF67ADQ38003074-B369D2DE-170D-4EDC-8A5C-36E5B778546BQ38014498-C7516CD9-67D8-4085-9F14-97BA14F05D21Q38035223-C189157C-276E-479A-9D7A-285B8A94AAC3Q38052101-A835D1F1-957F-4ECF-B7BD-7B5CA21F214DQ38099215-92D3C26A-0A7C-4A20-AA3E-E7232E761091Q38099268-CA7D4C57-A105-4BC6-82D5-3F11175122A0Q38099390-A45C679F-6FE9-47E8-97FE-58FF7754CA9FQ38125094-9E06B533-C06B-46EF-856A-C7A5E841EC77Q38866281-AB00E444-458D-4D51-A764-23D9094BD4AEQ39607350-5A53D4B8-BD00-4A3C-BA77-F20682167A08
P2860
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Chemotherapy and role of the p ...... gestive neuroendocrine tumors.
@en
type
label
Chemotherapy and role of the p ...... gestive neuroendocrine tumors.
@en
prefLabel
Chemotherapy and role of the p ...... gestive neuroendocrine tumors.
@en
P2093
P356
P1476
Chemotherapy and role of the p ...... gestive neuroendocrine tumors.
@en
P2093
Eduardo Vilar
Javier Cortes
Jose Pérez-García
Kjell Oberg
Ramón Salazar
P304
P356
10.1677/ERC-06-0074
P577
2007-06-01T00:00:00Z